1
|
Patel V, Aggarwal P, Sarvaiya J, Maity P, Ravichandiran V, Kaity S. Exploring novel and fast stability or sameness evaluation tool for different categories of injectable formulations. Eur J Pharm Sci 2023; 190:106551. [PMID: 37562551 DOI: 10.1016/j.ejps.2023.106551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 06/19/2023] [Accepted: 07/30/2023] [Indexed: 08/12/2023]
Abstract
The establishment of drug product stability and sameness is the heart of generic formulation development. For regulatory filing, various instrumental methods are used on a case basis to establish the generic and innovator product sameness in multiple aspects. Here in the present study, we explored the applicability of the Time-correlated single photon counting (TCS-PC) technique as a fast, reliable, and nondestructive method for establishing the sameness of three different categories of injectable formulations, namely, Amphotericin B liposome for injection, enoxaparin injection, and iron sucrose injection. All three category formulations were evaluated in their native and artificially induced post degradation state to identify the discrimination power of the used instrumental techniques. The degradation of materials were confirmed by high performance liquid chromatography (HPLC). Based on the product category, pre and post-degradation samples were evaluated by selective instrumental methods like differential scanning calorimetry (DSC), nuclear magnetic resonance (NMR), fluorescence spectroscopy, particle size analysis by dynamic light scattering (DLS), small angle X-ray scattering (SAXS), Raman spectroscopy, inductively coupled plasma optical-emission spectrometry (ICP-OES) and circular dichroism study. All pre and post-degradation samples were further analyzed by TCS-PC. We observed that, TCS-PC can identify the differences between the initial and post degradation samples in very less time with promising discrimination power across the different injectable formulation types. Thus TCS-PC can be used as a fast and promising stability or sameness evaluation tool for different injectable drug products.
Collapse
Affiliation(s)
- Vaibhavi Patel
- School of Engineering and Technology, National Forensic Sciences University, Gandhinagar, Gujarat, India
| | - Punita Aggarwal
- School of Engineering and Technology, National Forensic Sciences University, Gandhinagar, Gujarat, India; National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, West Bengal, India
| | - Jayrajsinh Sarvaiya
- Center of Excellence FTF, National Forensic Sciences University, Gandhinagar, Gujarat, India
| | - Prasenjit Maity
- School of Engineering and Technology, National Forensic Sciences University, Gandhinagar, Gujarat, India
| | - Velayutham Ravichandiran
- National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, West Bengal, India
| | - Santanu Kaity
- National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, West Bengal, India.
| |
Collapse
|
2
|
Krupnik L, Joshi P, Kappler A, Flühmann B, Alston AB, Digigow R, Wick P, Neels A. Critical nanomaterial attributes of iron-carbohydrate nanoparticles: Leveraging orthogonal methods to resolve the 3-dimensional structure. Eur J Pharm Sci 2023; 188:106521. [PMID: 37423578 DOI: 10.1016/j.ejps.2023.106521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Revised: 06/08/2023] [Accepted: 07/06/2023] [Indexed: 07/11/2023]
Abstract
Intravenous iron-carbohydrate nanomedicines are widely used to treat iron deficiency and iron deficiency anemia across a wide breadth of patient populations. These colloidal solutions of nanoparticles are complex drugs which inherently makes physicochemical characterization more challenging than small molecule drugs. There have been advancements in physicochemical characterization techniques such as dynamic light scattering and zeta potential measurement, that have provided a better understanding of the physical structure of these drug products in vitro. However, establishment and validation of complementary and orthogonal approaches are necessary to better understand the 3-dimensional physical structure of the iron-carbohydrate complexes, particularly with regard to their physical state in the context of the nanoparticle interaction with biological components such as whole blood (i.e. the nano-bio interface).
Collapse
Affiliation(s)
- Leonard Krupnik
- Laboratory for Particles-Biology Interactions, Materials meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen, Switzerland; Center for X-ray Analytics, Materials meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen, Switzerland; Department of Chemistry, University of Fribourg, Fribourg 1700, Switzerland
| | - Prachi Joshi
- Geomicrobiology, Department of Geosciences, University of Tuebingen, Tuebingen 72076, Germany
| | - Andreas Kappler
- Geomicrobiology, Department of Geosciences, University of Tuebingen, Tuebingen 72076, Germany; Cluster of Excellence: EXC 2124: Controlling Microbes to Fight Infection, Tuebingen 72076, Germany
| | - Beat Flühmann
- CSL Vifor, Flughofstrasse 61, Glattbrug 8152, Switzerland
| | | | | | - Peter Wick
- Laboratory for Particles-Biology Interactions, Materials meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen, Switzerland
| | - Antonia Neels
- Center for X-ray Analytics, Materials meet Life, Swiss Federal Laboratories for Materials Science and Technology (Empa), St. Gallen, Switzerland; Department of Chemistry, University of Fribourg, Fribourg 1700, Switzerland
| |
Collapse
|
3
|
Zagalo DM, Simões S, Sousa J. Regulatory Science Approach in Pharmaceutical Development of Follow-On Versions of Non-Biological Complex Drug Products. J Pharm Sci 2022; 111:2687-2713. [PMID: 35901943 DOI: 10.1016/j.xphs.2022.07.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 07/19/2022] [Accepted: 07/19/2022] [Indexed: 10/16/2022]
Abstract
Scientific and technological breakthroughs in the field of Nanotechnology have been a driving force throughout the development and approval of Non-Biological Complex Drugs (NBCDs). However, the fast-growing expansion of NBCDs and the emergence of their follow-on versions have brought with them several scientific, technological, and regulatory challenges. The definition of NBCDs is still not officially recognized by the regulatory authorities, and there is no dedicated regulatory pathway addressing the particular features of NBCDs and their follow-on versions. The lack of clear and consistent regulatory guidance documents in this field, as well as, the inconsistency across different regulatory agencies, impact negatively on the acceptance and enormous potential of these drug products. Patient access to high-quality NBCDs follow-on versions may be compromised by regulatory uncertainty resulting from the use of different regulatory approaches across the globe, as well as within the same class of products. Accordingly, there is a real need to develop a specific regulatory pathway compliant with the complexity of NBCDs and their follow-on versions or, alternatively, make better use of available regulatory pathways. The main goal of the review is to deeply investigate and provide a critical overview of the regulatory landscape of NBCDs and follow-on versions currently adopted by the regulatory authorities. The dissemination of knowledge and discussion in this field can contribute to clarifying regulations, policies, and regulatory approaches to complex generics, thereby filling regulatory and scientific gaps in the establishment of therapeutic equivalence.
Collapse
Affiliation(s)
- Daniela M Zagalo
- Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Bluepharma - Indústria Farmacêutica, São Martinho do Bispo, 3045-016 Coimbra, Portugal..
| | - Sérgio Simões
- Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Bluepharma - Indústria Farmacêutica, São Martinho do Bispo, 3045-016 Coimbra, Portugal
| | - João Sousa
- Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Coimbra Chemistry Centre, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal
| |
Collapse
|
4
|
Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics. Int J Mol Sci 2022; 23:ijms23042140. [PMID: 35216261 PMCID: PMC8878488 DOI: 10.3390/ijms23042140] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 02/04/2022] [Accepted: 02/09/2022] [Indexed: 01/27/2023] Open
Abstract
Un-complexed polynuclear ferric oxyhydroxide cannot be administered safely or effectively to patients. When polynuclear iron cores are formed with carbohydrates of various structures, stable complexes with surface carbohydrates driven by multiple interacting sites and forces are formed. These complexes deliver iron in a usable form to the body while avoiding the serious adverse effects of un-complexed forms of iron, such as polynuclear ferric oxyhydroxide. The rate and extent of plasma clearance and tissue biodistribution is variable among the commercially available iron–carbohydrate complexes and is driven principally by the surface characteristics of the complexes which dictate macrophage opsonization. The surface chemistry differences between the iron–carbohydrate complexes results in significant differences in in vivo pharmacokinetic and pharmacodynamic profiles as well as adverse event profiles, demonstrating that the entire iron–carbohydrate complex furnishes the pharmacologic action for these complex products. Currently available physicochemical characterization methods have limitations in biorelevant matrices resulting in challenges in defining critical quality attributes for surface characteristics for this class of complex nanomedicines.
Collapse
|
5
|
Hertig JB, Shah VP, Flühmann B, Mühlebach S, Stemer G, Surugue J, Moss R, Di Francesco T. Tackling the challenges of nanomedicines: are we ready? Am J Health Syst Pharm 2021; 78:1047-1056. [PMID: 33599767 PMCID: PMC7929390 DOI: 10.1093/ajhp/zxab048] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
PURPOSE This review provides an overview of the proceedings of the symposium "Tackling the Challenges of Nanomedicines: Are We Ready?" organized by the International Pharmaceutical Federation (FIP) Hospital Pharmacy Section and Non-Biological Complex Drugs (NBCDs) Working Group at the 2019 FIP World Congress of Pharmacy and Pharmaceutical Sciences. Debate centered on reasons underlying the current complex regulatory landscape for nanomedicines and their follow-on products (referred to as nanosimilars) and the pivotal role of hospital pharmacists in selecting, handling, and guiding usage of nanomedicines and nanosimilars. SUMMARY The evaluation and use of nanomedicines are recognized among scientific, pharmaceutical, and regulatory bodies as complex. Interchangeability and substitutability of nanomedicines and nanosimilars are confounded by a lack of pharmaceutical and pharmacological equivalence, reflecting the inherent complex nature of these drug products and manufacturing processes. Consequences include implications for clinical safety and efficacy and, ultimately, comparability. Local regulatory approvals of some nanomedicines have occurred, but there is no standard to ensure streamlined evaluation and use of consistent measures of therapeutic equivalence of reference products and their nanosimilars. Hospital pharmacists are expected to be experts in the selection, handling, and substitution of nanomedicines and familiarize themselves with the limitations of current methods of assessing pharmaceutical and clinical equivalence of nanosimilars in order to ensure informed formulary decision-making and eventual patient benefit. CONCLUSION Supportive guidance for pharmacists focusing on the substitutability and/or interchangeability of nanomedicines and their nanosimilars is needed. Current FIP guidance for pharmacists on therapeutic interchange and substitution should be extended to include nanomedicines and nanosimilars.
Collapse
Affiliation(s)
- John B Hertig
- Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA
| | | | | | - Stefan Mühlebach
- Division of Clinical Pharmacy & Epidemiology and Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Gunar Stemer
- Pharmacy Department, Vienna General Hospital–Medical University Campus, Vienna, Austria
| | - Jacqueline Surugue
- Hospital Pharmacy Department, Georges Renon General Hospital, Niort, France
| | - Rob Moss
- Hospital Pharmacy Section, International Pharmaceutical Federation, The Hague, Netherlands
| | | |
Collapse
|
6
|
Gaspar RS, Silva-Lima B, Magro F, Alcobia A, da Costa FL, Feio J. Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision. Front Med (Lausanne) 2020; 7:590527. [PMID: 33330550 PMCID: PMC7719831 DOI: 10.3389/fmed.2020.590527] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2020] [Accepted: 09/30/2020] [Indexed: 01/07/2023] Open
Abstract
Non-Biological Complex Drugs (NBCDs) are complex non-biological drugs comprised of large high molecular weight molecules and, often, nanoparticular structures (including liposomes and block-copolymer micelles). In the case of NBCDs, the entire complex is the active pharmaceutical ingredient and its properties cannot be fully characterized by physicochemical analysis. Moreover, the manufacturing process is fundamental in creating the correct originator product. The same is true for generic versions of the product. A recent appraisal of approval procedures for NBCDs "follow-on products" approved in Europe shows a diversity of regulatory pathways. In fact, three different abridged application procedures, under European legislation, were used: the generic application procedure of Article 10(1), the hybrid application procedure of Article 10(3), and the biosimilar application procedure of Article 10(4). Three informed consent applications via Article 10(c) from innovator companies of glatiramer acetate and sevelamer carbonate were submitted shortly after the approval of the first follow-on products. Furthermore, a number of "well-established use" applications [via Article 10(a)] were approved for iron sucrose and iron dextran complexes. In order to protect patients from the increased risks of NBCD products and NBCD follow-on products, two complementary approaches should be considered: (i) improving the regulatory procedures and their guidance documents within the pre-registration phase, and (ii) not considering interchangeability whenever clinical data is not available. With regards to the latter, the need for adequate safety and efficacy data might also include risk management programmes within post-approval pharmacovigilance actions. This, however, would depend on a risk appraisal that must be considered for individual medicinal products, based on the nature of the submitted relevant set of safety/efficacy data.
Collapse
Affiliation(s)
- Rogério Sá Gaspar
- Departamento de Sócio Farmácia, Faculdade de Farmácia, Universidade de Lisboa,Lisboa, Portugal
- Institute for Biosciences and Bioengineering (iBB), Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
| | - Beatriz Silva-Lima
- Departamento de Ciências Farmacológicas, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal
- Research Institute for Medicines (iMed), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal
| | - Fernando Magro
- Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal
- Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal
- Center for Drug Discovery and Innovative Medicines (MedInUp), University of Porto, Porto, Portugal
- Unidade de Farmacologia Clínica, Centro Hospitalar Universitário de S. João, Porto, Portugal
| | - Armando Alcobia
- Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal
- Serviços Farmacêuticos, Hospital Garcia de Orta, Almada, Portugal
| | - Fernando Leal da Costa
- Center for Drug Discovery and Innovative Medicines (MedInUp), University of Porto, Porto, Portugal
- Instituto Português de Oncologia de Lisboa, Lisboa, Portugal
| | - José Feio
- Unidade de Farmacologia Clínica, Centro Hospitalar Universitário de S. João, Porto, Portugal
- Serviços Farmacêuticos, Centro Hospitalar Universitário de Coimbra (CHUC), Coimbra, Portugal
| |
Collapse
|
7
|
Nanomedicines: The magic bullets reaching their target? Eur J Pharm Sci 2018; 128:73-80. [PMID: 30465818 DOI: 10.1016/j.ejps.2018.11.019] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Revised: 10/29/2018] [Accepted: 11/18/2018] [Indexed: 12/11/2022]
Abstract
Nanomedicines, since the approval of the first one in the 1950s, have been accompanied by expectations of higher efficiency and efficacy, compared to less complex drugs. The fulfilment of those expectations has been slower than anticipated, due to the high complexity of nanomedicine drugs combined with a lack of scientific understanding of nanomedicine interactions with biological systems. The unique properties of their size and their surface composition create difficulties in their physicochemical characterization, and as a consequence, difficulty in assessing the similarity of follow-on products (nanosimilars) to originator nanomedicines. During the 2018 European Federation for Pharmaceutical Sciences (EUFEPS) annual meeting "Crossing the barrier for future medicines" in Athens, there were several sessions on nanomedicines organised by the EUFEPS Nanomedicine Network. This review focuses on the session "Nanomedicines and nanosimilars: how to assess similar?", discussing the nature of nanomedicines, the regulatory aspects of the topic and the impact of practical use and handling of such medicinal products. Emphasis is put on the consequences their nanosize-related properties have on the establishment of their critical quality attributes and how this affects the demonstration of bioequivalence of nanosimilars to their originator products. The lack of an appropriate and harmonized regulatory evaluation procedure and the absence of corresponding education are also discussed, especially the uncertainty surrounding the practical use of nanosimilars, including the higher healthcare cost due to less than satisfactory number of safe and efficacious nanosimilars in the market.
Collapse
|